Atopic Dermatitis Agents – Monoclonal Antibodies

WA.PHAR.41 Atopic Dermatitis Agents Monoclonal Antibodies

Related medical policies:
- Atopic Dermatitis Agents – Topical Immunosuppressive
- Atopic Dermatitis Agents – Topical Phosphodiesterase 4 (PDE4) Inhibitors

Background:
Atopic dermatitis (AD) is a chronic, non-contagious, inflammatory disease of the skin resulting from a combination of genetic and environmental factors. Often referred to as “eczema,” it is characterized by extremely dry, itchy skin on the insides of the elbows, behind the knees, and on the face, hands, and feet.

Medical Necessity

<table>
<thead>
<tr>
<th>Drug</th>
<th>Medical Necessity</th>
</tr>
</thead>
<tbody>
<tr>
<td>dupilumab (Dupixent®)</td>
<td>Dupixent® may be considered medically necessary when: Used for the treatment of severe chronic atopic dermatitis in adults</td>
</tr>
</tbody>
</table>

Clinical policy:

<table>
<thead>
<tr>
<th>Drug</th>
<th>Clinical Criteria (Initial Approval)</th>
</tr>
</thead>
<tbody>
<tr>
<td>dupilumab (Dupixent®)</td>
<td>Dupixent® may be covered when ALL of the following are met:</td>
</tr>
<tr>
<td></td>
<td>1. Diagnosis of severe chronic atopic dermatitis involving at least 10% of body surface area (BSA)</td>
</tr>
<tr>
<td></td>
<td>2. Clinical documentation of functional impairment due to atopic dermatitis, which may include (but is not limited to) documentation of limitation of activities of daily living (ADLs), skin infections or sleep disturbances.</td>
</tr>
<tr>
<td></td>
<td>3. History of failure (unable to achieve or maintain remission of low or mild disease), intolerance, contraindication or clinically inappropriate to daily use of the following:</td>
</tr>
<tr>
<td></td>
<td>a. Two topical corticosteroids for daily treatment of minimum 14-days each</td>
</tr>
<tr>
<td></td>
<td>i. Adults: Failure of 2 high or very high potency corticosteroids in the previous 6 months, unless member has contraindication(s) to all preferred topical corticosteroids</td>
</tr>
<tr>
<td></td>
<td>b. Topical calcineurin inhibitors (e.g. pimecrolimus, tacrolimus) daily treatment for at least 28-days</td>
</tr>
<tr>
<td></td>
<td>c. ONE of the following:</td>
</tr>
</tbody>
</table>

Policy: Atopic Dermatitis Agents
- Monoclonal Antibodies

Last Updated 04/18/2018
i. Phototherapy
ii. Systemic treatment with immunosuppressants, such as methotrexate, cyclosporine, azathioprine, mycophenolate

4. Greater than or equal to (≥) 18 years of age
5. Prescribed by or in consultation with a specialist in dermatology, allergy or pulmonology.

**Approve for 3 months**

**Criteria (Reauthorization)**

Documentation of decrease in BSA involvement and resolution of associated symptoms (e.g. pruritis, inflammation, redness, etc)

**Approve for 6 months**

---

### Dosage and quantity limits

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Dose and Quantity Limits</th>
</tr>
</thead>
<tbody>
<tr>
<td>dupilumab (Dupixent®)</td>
<td>Initial dose of 600mg (two 300mg injections), followed by 300mg every other week</td>
</tr>
</tbody>
</table>
References


Policy: Atopic Dermatitis Agents
- Monoclonal Antibodies

Last Updated 04/18/2018